Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
Provided By GlobeNewswire
Last update: Dec 10, 2024
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025
APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus monotherapy
Read more at globenewswire.com
